An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

IF 2.9 3区医学 Q2 ONCOLOGY

Expert Review of Anticancer Therapy Pub Date : 2024-12-01 Epub Date: 2024-12-25 DOI:10.1080/14737140.2024.2445152

Riccardo Serra, Emilio Francesco Giunta, Giuseppe Schepisi, Nicole Brighi, Daniela Montanari, Cristian Lolli, Sara Bleve, Margherita Piras, Giuseppe Palmieri, Mario Scartozzi, Panagiotis Paliogiannis, Ugo De Giorgi

{"title":"An evaluation of talazoparib plus enzalutamide for the treatment of metastatic castration-resistant prostate cancer.","authors":"Riccardo Serra, Emilio Francesco Giunta, Giuseppe Schepisi, Nicole Brighi, Daniela Montanari, Cristian Lolli, Sara Bleve, Margherita Piras, Giuseppe Palmieri, Mario Scartozzi, Panagiotis Paliogiannis, Ugo De Giorgi","doi":"10.1080/14737140.2024.2445152","DOIUrl":null,"url":null,"abstract":"Introduction: Prostate cancer (PCa) is the second most common cancer diagnosis among men worldwide, with poor prognosis in its advanced stage. Treatment strategies have evolved, including the use of androgen receptor pathway inhibitors (ARPIs) and poly (ADP-ribose) polymerase inhibitors (PARPis).Areas covered: This review evaluates the clinical efficacy, safety, and future potential of combining talazoparib, a potent PARPi, with enzalutamide, a strong androgen receptor (AR) antagonist. The combination of these two drugs was evaluated by the TALAPRO-2 trial, demonstrating significant improvement in radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) patients, particularly those with Homologous Recombination Repair (HRR) gene mutations such as BRCA1/2.Expert opinion: Emerging biomarkers like TMPRSS2-ERG and RB1 gene mutations have been recently reported as potential predictors of clinical outcome in the TALAPRO-2 all-comers population. Genomic markers for homologous recombination deficiency (HRD) are other potential drivers of response to PARPi/ARPI combination. Further investigation is needed to refine treatment strategies, including targeting non-HRR mutations, and to expand the role of this combination therapy in earlier stages of prostate cancer.","PeriodicalId":12099,"journal":{"name":"Expert Review of Anticancer Therapy","volume":" ","pages":"1221-1227"},"PeriodicalIF":2.9000,"publicationDate":"2024-12-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Expert Review of Anticancer Therapy","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/14737140.2024.2445152","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2024/12/25 0:00:00","PubModel":"Epub","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: Prostate cancer (PCa) is the second most common cancer diagnosis among men worldwide, with poor prognosis in its advanced stage. Treatment strategies have evolved, including the use of androgen receptor pathway inhibitors (ARPIs) and poly (ADP-ribose) polymerase inhibitors (PARPis).

Areas covered: This review evaluates the clinical efficacy, safety, and future potential of combining talazoparib, a potent PARPi, with enzalutamide, a strong androgen receptor (AR) antagonist. The combination of these two drugs was evaluated by the TALAPRO-2 trial, demonstrating significant improvement in radiographic progression-free survival (rPFS) in metastatic castration-resistant prostate cancer (mCRPC) patients, particularly those with Homologous Recombination Repair (HRR) gene mutations such as BRCA1/2.

Expert opinion: Emerging biomarkers like TMPRSS2-ERG and RB1 gene mutations have been recently reported as potential predictors of clinical outcome in the TALAPRO-2 all-comers population. Genomic markers for homologous recombination deficiency (HRD) are other potential drivers of response to PARPi/ARPI combination. Further investigation is needed to refine treatment strategies, including targeting non-HRR mutations, and to expand the role of this combination therapy in earlier stages of prostate cancer.

查看原文本刊更多论文

talazoparib联合enzalutamide治疗转移性去势抵抗性前列腺癌的评价。

简介：前列腺癌（PCa）是全球男性中第二常见的癌症诊断，其晚期预后较差。治疗策略已经发展，包括雄激素受体途径抑制剂（ARPIs）和聚（adp -核糖）聚合酶抑制剂（PARPis）的使用。涵盖领域：本综述评估了talazoparib（一种有效的PARPi）与enzalutamide（一种强雄激素受体（AR）拮抗剂）联合使用的临床疗效、安全性和未来潜力。TALAPRO-2试验评估了这两种药物的联合使用，显示转移性去势抵抗性前列腺癌（mCRPC）患者的放射无进展生存期（rPFS）显著改善，特别是那些同源重组修复（HRR）基因突变如BRCA1/2的患者。专家意见：新兴的生物标志物，如TMPRSS2-ERG和RB1基因突变，最近被报道为TALAPRO-2所有患者临床结果的潜在预测因素。同源重组缺陷（HRD）的基因组标记是PARPi/ARPI联合反应的其他潜在驱动因素。需要进一步的研究来完善治疗策略，包括针对非hrr突变，并扩大这种联合治疗在前列腺癌早期阶段的作用。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Expert Review of Anticancer Therapy 医学-肿瘤学

CiteScore

5.10

自引率

3.00%

发文量

100

审稿时长

4-8 weeks

期刊介绍： Expert Review of Anticancer Therapy (ISSN 1473-7140) provides expert appraisal and commentary on the major trends in cancer care and highlights the performance of new therapeutic and diagnostic approaches. Coverage includes tumor management, novel medicines, anticancer agents and chemotherapy, biological therapy, cancer vaccines, therapeutic indications, biomarkers and diagnostics, and treatment guidelines. All articles are subject to rigorous peer-review, and the journal makes an essential contribution to decision-making in cancer care. Comprehensive coverage in each review is complemented by the unique Expert Review format and includes the following sections: Expert Opinion - a personal view of the data presented in the article, a discussion on the developments that are likely to be important in the future, and the avenues of research likely to become exciting as further studies yield more detailed results Article Highlights – an executive summary of the author’s most critical points.